Instituto de Neurociencias, Universidad de Granada, Granada, Spain.
J Altern Complement Med. 2013 Mar;19(3):238-42. doi: 10.1089/acm.2011.0739. Epub 2012 Oct 9.
The objectives of this study were to evaluate the effectiveness and tolerability of ozone therapy by rectal insufflation as add-on therapy in fibromyalgia management.
Patients with fibromyalgia received 24 sessions of ozone therapy during a 12-week period. At each session, the administered dose of ozone was 8 mg (200 mL of gas, at a concentration of 40 μg/mL). Ozone sessions were given 5 days a week during the first 2 weeks, twice a week from weeks 3-6, and weekly from weeks 7-12. Fibromyalgia Impact Questionnaire (FIQ) was the main outcome measure, and was administered at baseline and at weeks 4, 8, and 12. Secondary outcome measures, administered at baseline and at endpoint, were the Pittsburgh Sleep Quality Index, the Beck Depression Inventory, the State and Trait Anxiety Inventory, and the SF-12, the abbreviated form of the Short Form Health Survey. Emergent adverse reactions to treatment were recorded.
FIQ total scores decreased significantly during the study period, with the decrease being observed in the first 4 weeks of the study. Significant improvement was also seen both in depression scores and in the Physical Summary Score of the SF-12. Transient meteorism after ozone therapy sessions was the most frequently reported side-effect.
At the dose and number of sessions used in this study, ozone therapy by rectal insufflation seems to be beneficial for physical symptoms and depression of fibromyalgia.
本研究旨在评估直肠内吹入臭氧疗法作为纤维肌痛管理辅助疗法的有效性和耐受性。
纤维肌痛患者在 12 周内接受 24 次臭氧治疗。每次治疗时给予的臭氧剂量为 8 毫克（200 毫升气体，浓度为 40 μg/ml）。在前 2 周，每周治疗 5 天，第 3-6 周每周治疗 2 次，第 7-12 周每周治疗 1 次。主要观察指标为纤维肌痛影响问卷（FIQ），在基线和第 4、8、12 周进行评估。次要观察指标在基线和终点时进行评估，包括匹兹堡睡眠质量指数、贝克抑郁量表、状态-特质焦虑量表和 SF-12，SF-12 是健康调查简表的缩写形式。记录治疗过程中出现的不良反应。
FIQ 总分在研究期间显著下降，在研究的前 4 周观察到下降。抑郁评分和 SF-12 的身体总分也有显著改善。臭氧治疗后短暂出现的气胀是最常报告的副作用。
在本研究中使用的剂量和治疗次数下，直肠内吹入臭氧疗法似乎对纤维肌痛的躯体症状和抑郁有益。
